Photocure ASA
OSE:PHO

Watchlist Manager
Photocure ASA Logo
Photocure ASA
OSE:PHO
Watchlist
Price: 48.7 NOK -3.56% Market Closed
Market Cap: 1.3B NOK
Have any thoughts about
Photocure ASA?
Write Note

Photocure ASA
Cash from Financing Activities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Photocure ASA
Cash from Financing Activities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash from Financing Activities CAGR 3Y CAGR 5Y CAGR 10Y
Photocure ASA
OSE:PHO
Cash from Financing Activities
-kr47.5m
CAGR 3-Years
-91%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
V
Vistin Pharma ASA
OSE:VISTN
Cash from Financing Activities
-kr12.6m
CAGR 3-Years
23%
CAGR 5-Years
-69%
CAGR 10-Years
N/A
N
Navamedic ASA
OSE:NAVA
Cash from Financing Activities
kr2.4m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
-12%
S
SoftOx Solutions AS
OSE:SOFTX
Cash from Financing Activities
kr15.5m
CAGR 3-Years
-39%
CAGR 5-Years
97%
CAGR 10-Years
N/A
No Stocks Found

Photocure ASA
Glance View

Market Cap
1.3B NOK
Industry
Pharmaceuticals

Photocure ASA delivers transformative solutions to improve the lives of bladder cancer patients. The company is headquartered in Oslo, Oslo. The company went IPO on 2000-05-29. The company operates in the field of photodynamic diagnosis, cosmetics and treatment of acne, bladder cancer, colon cancer, as well as human papilloma virus (HPV) and precancerous lesions of the cervix. The Company’s activities comprise research, development and commercialization of pipeline projects within two segments: Cancer and Dermatology. Its brand portfolio includes: Hexvix and Cysview, for detection and management of bladder cancer; Visonac, for acne treatment; Cevira, used in HPV and precancerous lesions of the cervix treatment; and Lumacan, applied in colorectal cancer treatment. Furthermore, It owns a Photocure Technology platform, which develops photodynamic technology for diagnosis and therapy. The firm is a parent of a wholly owned entity, Photocure Inc.

PHO Intrinsic Value
69.23 NOK
Undervaluation 30%
Intrinsic Value
Price

See Also

What is Photocure ASA's Cash from Financing Activities?
Cash from Financing Activities
-47.5m NOK

Based on the financial report for Jun 30, 2024, Photocure ASA's Cash from Financing Activities amounts to -47.5m NOK.

What is Photocure ASA's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 3Y
-91%

Over the last year, the Cash from Financing Activities growth was 17%. The average annual Cash from Financing Activities growth rates for Photocure ASA have been -91% over the past three years .

Back to Top